Predictive Structure-based Guidelines for Identifying Optimal PEGylation Sites within Proteins and Understanding the Context-Dependence of Non-covalent Interaction Strength

Information

  • Research Project
  • 9965611
  • ApplicationId
    9965611
  • Core Project Number
    R15GM116055
  • Full Project Number
    2R15GM116055-02
  • Serial Number
    116055
  • FOA Number
    PAR-18-714
  • Sub Project Id
  • Project Start Date
    9/1/2015 - 9 years ago
  • Project End Date
    3/31/2023 - a year ago
  • Program Officer Name
    SMITH, WARD
  • Budget Start Date
    5/1/2020 - 4 years ago
  • Budget End Date
    3/31/2023 - a year ago
  • Fiscal Year
    2020
  • Support Year
    02
  • Suffix
  • Award Notice Date
    4/22/2020 - 4 years ago
Organizations

Predictive Structure-based Guidelines for Identifying Optimal PEGylation Sites within Proteins and Understanding the Context-Dependence of Non-covalent Interaction Strength

Predictive Structure-based Guidelines for Identifying Optimal PEGylation Sites within Proteins and Understanding the Context-Dependence of Non-covalent Interaction Strength Our goal is to develop structure-based tools for identifying optimal PEGylation sites within peptides/proteins and to use these tools to enhance peptide/protein pharmacokinetic properties. Our central hypothesis is that optimal PEGylation sites should be characterized by the ability of the attached PEG to enhance peptide/protein conformational stability. Our rationale for this hypothesis is that unstable, unfolded or misfolded proteins tend to be non-functional and have more pharmacokinetic problems than folded proteins (i.e., are more aggregation- prone, more susceptible to proteolysis, and more readily recognized by antibodies). Therefore increases in protein conformational stability should also enhance protein pharmacokinetic properties However, current PEGylation efforts lack predictive tools for increasing protein stability; instead, a trial-and-error approach prevails, which frequently results in diminished biological activity relative to the non-PEGylated protein. Using our growing molecular-level understanding of PEG-based protein stabilization, we will develop predictive structure-based tools for generating PEGylated peptides/proteins with enhanced pharmacokinetic properties and undiminished function, thereby accelerating the development of better PEGylated protein drugs. We also seek to understand and predict how location, microenvironment, and structural context affect the strength of non-covalent interactions, including salt-bridges, cation-? interactions, and n to ?* interactions, among others.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R15
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
    300000
  • Indirect Cost Amount
    135750
  • Total Cost
    435750
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIGMS:435750\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    SBCB
  • Study Section Name
    Synthetic and Biological Chemistry B Study Section
  • Organization Name
    BRIGHAM YOUNG UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    009094012
  • Organization City
    PROVO
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    846021001
  • Organization District
    UNITED STATES